Online citations, reference lists, and bibliographies.

Development And Application Of A Multi-component LC-MS/MS Method For Determination Of Designer Benzodiazepines In Urine.

Madeleine Pettersson Bergstrand, A. Helander, O. Beck
Published 2016 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
New psychoactive substances (NPS) have become an increasing drug problem in the past decade. For detection of NPS, new analytical methods have to be developed, and the methods also have to be updated regularly. This study aimed at developing a multi-component LC-MS/MS method for detection and quantification of 11 NPS of the benzodiazepine sub-class ("designer benzodiazepines") in urine specimens. The method involves dilution of urine with internal standard and hydrolysis of any glucuronide conjugated forms. Separation of the compounds was achieved on a BEH Phenyl column, followed by MS/MS detection in positive electrospray mode. Method validation was performed following the EMA guideline. The method was applied to study the occurrence of designer benzodiazepines in Sweden in 2014-2015, by analysis of 390 samples retrieved from a routine drug testing laboratory. In 40% of these samples, selected based on a positive immunoassay benzodiazepine screening but a negative MS confirmation for the standard set of prescription benzodiazepines, intake of designer benzodiazepines was revealed. These results stress the importance of using and updating confirmation methods to include the increasing number of designer benzodiazepines appearing on the NPS market.
This paper references
10.1159/000259159
European Monitoring Centre for Drugs and Drug Addiction
M. Anderson (2014)
10.1016/j.forsciint.2016.02.017
A fatal intoxication related to MDPV and pentedrone combined with antipsychotic and antidepressant substances in Cyprus.
Katerina Liveri (2016)
10.1016/j.forsciint.2008.08.012
Case report: Etizolam and its major metabolites in two unnatural death cases.
Takuma Nakamae (2008)
10.1016/S0003-2670(03)00304-0
Simple method for the determination of benzodiazepines in human body fluids by high-performance liquid chromatography–mass spectrometry
X. Lee (2003)
10.1016/0378-4347(96)00121-1
Simultaneous determination of twelve benzodiazepines in human serum using a new reversed-phase chromatographic column on a 2-microns porous microspherical silica gel.
E. Tanaka (1996)
10.3109/00365513.2013.793817
Identification of novel psychoactive drug use in Sweden based on laboratory analysis – initial experiences from the STRIDA project
A. Helander (2013)
10.1002/jps.2600691124
Reversible ring-opening reactions of nimetazepam and nitrazepam in acidic media at body temperature.
N. Inotsume (1980)
10.1016/j.jchromb.2011.10.033
Determination of benzodiazepines in ante-mortem and post-mortem whole blood by solid-supported liquid-liquid extraction and UPLC-MS/MS.
E. Sauvé (2012)
Comparisation of drugs used by nightclub patrons and criminal offenders in Olso
H Gjerde (2016)
10.1007/s11419-013-0187-4
Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine
Bjoern Moosmann (2013)
10.1016/j.jchromb.2013.04.043
Multicomponent LC-MS/MS screening method for detection of new psychoactive drugs, legal highs, in urine-experience from the Swedish population.
Yasir Al-Saffar (2013)
10.1007/s11419-015-0277-6
Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites
Laura M Huppertz (2015)
10.1002/jps.2600720409
Kinetics and equilibrium of the reversible alprazolam ring-opening reaction.
M. Cho (1983)
10.1016/j.forsciint.2014.02.022
Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project.
Anders Helander (2014)
10.1016/j.drugalcdep.2012.07.004
Polydrug abuse: a review of opioid and benzodiazepine combination use.
J. Jones (2012)
10.1093/jat/bkv111
Ultra Performance Liquid Chromatography with Tandem Mass Spectrometry for the Quantitation of Seventeen Sedative Hypnotics in Six Common Toxicological Matrices.
Dani C Mata (2016)
10.1016/j.forsciint.2015.12.029
Comparison of drugs used by nightclub patrons and criminal offenders in Oslo, Norway.
Hallvard Gjerde (2016)
10.1093/jat/bks080
Phenazepam and its effects on driving.
Jon B. Stephenson (2013)
10.1002/dta.2003
Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.
Madeleine Pettersson Bergstrand (2017)
10.1016/S0379-0738(00)00226-7
Screening and determination of benzodiazepines in whole blood using solid-phase extraction and gas chromatography/mass spectrometry.
H. Inoue (2000)
10.1016/J.JCHROMB.2004.04.039
Confirmatory analysis for drugs of abuse in plasma and urine by high-performance liquid chromatography-tandem mass spectrometry with respect to criteria for compound identification.
Barbora Maralíková (2004)
10.1016/0378-4347(85)80105-5
Plasma determination of 3-methylclonazepam by capillary gas chromatography.
Philippe Coassolo (1985)
10.3109/15563650.2015.1112907
Flubromazolam – A new life-threatening designer benzodiazepine
M. Łukasik-Głębocka (2016)
10.1007/s00216-016-9439-6
Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes
Markus R. Meyer (2016)
10.1002/dta.1628
Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics.
Bjoern Moosmann (2014)
10.1016/j.forsciint.2012.02.006
Phenazepam abuse in Finland: findings from apprehended drivers, post-mortem cases and police confiscations.
P. Kriikku (2012)
10.1002/jms.3279
Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics.
B. Moosmann (2013)
Comparisation of drugs used by nightclub patrons and criminal offenders in Olso , Norway
M. Pettersson Bergstrand (2016)
10.1016/j.forsciint.2015.01.003
Fatal poisoning in drug addicts in the Nordic countries in 2012.
K. Simonsen (2015)
10.1007/s11419-006-0011-5
Rapid and simple analysis of oxazolobenzodiazepine drugs in sera by wide-bore capillary gas chromatography with nitrogen-phosphorus detection using on-column methylation
M. Terada (2006)
Rang and Dale's pharmacology
H. Rang (2012)
10.1016/S0379-0738(01)00481-9
Flunitrazepam: an evaluation of use, abuse and toxicity.
H. Druid (2001)
10.1002/dta.1790
Analysis of phenazepam and 3-hydroxyphenazepam in post-mortem fluids and tissues.
Megan L. Crichton (2015)
[Creatinine concentration in urine should be measured in drug testing. Guidelines for decision limits and interpretation are necessary--at any rate for legal rights].
Anders Helander (2011)
10.1093/JAT/21.5.335
A sensitive GC-MS procedure for the analysis of flunitrazepam and its metabolites in urine.
M. ElSohly (1997)



This paper is referenced by
10.1093/jat/bkx031
Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013-2016: A Review.
B. Logan (2017)
10.1016/j.chroma.2017.06.010
Proposal of 5-methoxy-N-methyl-N-isopropyltryptamine consumption biomarkers through identification of in vivo metabolites from mice.
D Fabregat-Safont (2017)
10.1007/s00216-018-1147-y
Rapid determination of designer benzodiazepines, benzodiazepines, and Z-hypnotics in whole blood using parallel artificial liquid membrane extraction and UHPLC-MS/MS
Linda Vårdal (2018)
10.1016/j.neuro.2019.02.015
An expanding world of new psychoactive substances-designer benzodiazepines.
J. Zawilska (2019)
10.1373/JALM.2018.026658
Quantitation of Benzodiazepines and Metabolites in Urine by Liquid Chromatography–Tandem Mass Spectrometry
Yu Zi Zheng (2018)
10.25148/etd.FIDC006565
Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances
Joshua Z Seither (2018)
10.1002/dta.2561
Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864).
Bjoern Moosmann (2019)
10.1016/j.jchromb.2017.04.008
Ultrasound-assisted low-density solvent dispersive liquid-liquid microextraction for the determination of 4 designer benzodiazepines in urine samples by gas chromatography-triple quadrupole mass spectrometry.
Liang Meng (2017)
10.1080/24734306.2019.1661568
Clonazolam: a novel liquid benzodiazepine
Lauren Murphy (2019)
10.1093/jat/bkz063
Validation of an LC-MS/MS Method for the Quantification of 13 Designer Benzodiazepines in Blood.
Victoria Mei (2019)
10.1016/J.TOXAC.2017.12.001
Les « designer benzodiazepines » : qu’en sait-on aujourd’hui ?
Emil Chetraru (2018)
10.1093/jat/bky039
A Case Study Involving U-47700, Diclazepam and Flubromazepam-Application of Retrospective Analysis of HRMS Data.
E. M. Partridge (2018)
10.1080/15563650.2018.1506130
Occurrence and time course of NPS benzodiazepines in Sweden – results from intoxication cases in the STRIDA project
M. Bäckberg (2019)
Urine Testing and Abuse Patterns of Drugs and New Psychoactive Substances — Application of Comprehensive Time-of-Flight Mass Spectrometry
Antti-Pekka E. Rissanen (2017)
10.1016/J.CLINMS.2018.08.004
Urine analysis of 28 designer benzodiazepines by liquid chromatography–high-resolution mass spectrometry
Madeleine Pettersson Bergstrand (2018)
10.1016/j.talanta.2017.08.010
Simultaneous determination of designer benzodiazepines in human serum using non-aqueous capillary electrophoresis - Tandem mass spectrometry with successive multiple ionic - Polymer layer coated capillary.
Martin Švidrnoch (2018)
10.1007/164_2017_83
Bioanalytical Methods for New Psychoactive Substances.
Lea Wagmann (2018)
10.1016/j.jpba.2019.02.011
Quantification of eight benzodiazepines in human breastmilk and plasma by liquid‐liquid extraction and liquid‐chromatography tandem mass spectrometry: Application to evaluation of alprazolam transfer into breastmilk
Ayako Furugen (2019)
10.1002/dta.2243
Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography-high resolution mass spectrometry.
Madeleine Pettersson Bergstrand (2018)
10.3390/s19225002
Voltammetric Electronic Tongue for the Simultaneous Determination of Three Benzodiazepines
Anna Herrera-Chacón (2019)
10.1371/journal.pone.0232038
Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project
Anders Helander (2020)
10.1093/jat/bky092
A Liquid-Chromatography High-Resolution Mass Spectrometry Method for Non-FDA Approved Benzodiazepines.
Xander M R Van Wijk (2019)
10.1007/978-1-4939-8823-5_3
Analysis of Benzodiazepines for Drug-Facilitated Assaults and Abuse Settings (Urine).
Olaf H. Drummer (2019)
10.1002/dta.2349
The emergence of new psychoactive substance (NPS) benzodiazepines: A review.
Kieran R. Manchester (2018)
10.1002/dta.2203
Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine.
L. Huppertz (2018)
10.1007/s00414-017-1541-6
Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer
Souleiman El Balkhi (2017)
10.1002/dta.2211
The emergence of new psychoactive substance (NPS) benzodiazepines: A review.
Kieran R. Manchester (2018)
10.1007/164_2018_154
Designer Benzodiazepines: Another Class of New Psychoactive Substances.
B. Moosmann (2018)
10.1080/15563650.2018.1510502
Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014–2017
J. Carpenter (2019)
10.1002/jssc.201700069
Analysis of selected designer benzodiazepines by ultra high performance liquid chromatography with high-resolution time-of-flight mass spectrometry and the estimation of their partition coefficients by micellar electrokinetic chromatography.
Jana Tomková (2017)
10.1016/j.snb.2019.127441
A Carbon-Dot Sensing Probe for Screening of Date Rape Drugs: Nitro-containing Benzodiazepines
Yao-Te Yen (2020)
10.1002/ansa.202000027
Differentiation of ring‐substituted regioisomers of cathinone analogs by supercritical fluid chromatography
Hiroki Segawa (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar